A Study of Lobucavir in Patients With AIDS
Not Applicable
Completed
- Conditions
- Cytomegalovirus InfectionsHIV Infections
- Registration Number
- NCT00002352
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to see if lobucavir is a safe and effective treatment for cytomegalovirus in patients with AIDS.
- Detailed Description
Patients receive 1 of 2 doses of lobucavir for 28 days, with 2 weeks of follow-up. Weekly clinic visits are required.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Mount Zion Med Ctr / UCSF
🇺🇸San Francisco, California, United States
San Francisco Veterans Adm Med Cntr
🇺🇸San Francisco, California, United States
Univ of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Mount Zion Med Ctr / UCSF🇺🇸San Francisco, California, United States